At AAPS with CritiTech Particle Engineering Solutions

Published on: 

Matthew McClorey, President of CritiTech Particle Engineering Solutions, shares his insights at AAPS.

At a recent American Association of Pharmaceutical Scientists (AAPS) convention, BioPharm International sat down with Matthew McClorey, President of CritiTech Particle Engineering Solutions.

Learn more about:

  • What makes CritiTech unique in the CDMO market.
  • What you can expect from working with CritiTech.
  • The company’s ability to formulate direct-to-site treatments from previously systemically delivered drugs with the patented Purcision platform.